Q4 Earnings Forecast for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX) – Research analysts at HC Wainwright upped their Q4 2024 earnings per share (EPS) estimates for Metagenomi in a report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.52) per share for the quarter, up from their prior forecast of ($0.69). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

MGX has been the topic of several other research reports. BMO Capital Markets dropped their price target on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.50.

Metagenomi Price Performance

Shares of NASDAQ MGX opened at $1.89 on Monday. The business has a 50 day simple moving average of $2.06 and a 200 day simple moving average of $3.69. Metagenomi has a 52 week low of $1.61 and a 52 week high of $12.74.

Institutional Investors Weigh In On Metagenomi

Several hedge funds and other institutional investors have recently made changes to their positions in MGX. Vanguard Group Inc. bought a new stake in shares of Metagenomi in the first quarter valued at approximately $1,894,000. Green Alpha Advisors LLC bought a new stake in shares of Metagenomi in the 3rd quarter worth approximately $69,000. Rhumbline Advisers acquired a new stake in shares of Metagenomi during the 2nd quarter worth approximately $26,000. Novo Holdings A S increased its position in shares of Metagenomi by 3.5% during the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 60,825 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Metagenomi in the second quarter valued at $66,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.